-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35

Benzinga·10/05/2026 17:09:06
Listen to the news
Roth Capital analyst Boobalan Pachaiyappan downgrades LB Pharmaceuticals (NASDAQ:LBRX) from Buy to Neutral and lowers the price target from $37 to $35.